Treatment as required versus regular monthly treatment in the management of neovascular age-related macular degeneration: A systematic review and meta-analysis

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Schmucker, Christine M ^a   Rücker, Gerta ^a   Sommer, Harriet ^a   Virgili, Gianni ^b   Loke, Yoon K ^c   Oeller, Patrick ^a   Agostini, Hansjuergen ^a   Ehlken, Christoph ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN;

AGE RELATED MACULAR DEGENERATION; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; META ANALYSIS; MORPHOLOGY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RETINAL THICKNESS; SYSTEMATIC REVIEW; TIME TO TREATMENT; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL FIELD; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; PERSONALIZED MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTRAVITREAL INJECTIONS; PRECISION MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTORS; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84947436052     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137866     Document Type: Article

References (22)

1. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1432-44. PMID: 17021319.
2. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009; 116(1):57-65.e5. doi: 10.1016/j.ophtha.2008.10.018 PMID: 19118696.
3. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. PMID: 17021318.
4. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 2010; 150 (3):315-24.e1. doi: 10.1016/j.ajo.2010.04.011 PMID: 20598667.
5. Haller JA. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden. Ophthalmology. 2013; 120(5 Suppl):S3-7. Epub 2013/05/10. doi: 10.1016/j.ophtha.2013.01.057 PMID: 23642784.
6. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook. org.
7. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003; 327(7414):557-60. Epub 2003/09/06. doi: 10.1136/bmj.327.7414.557 PMID: 12958120; PubMed Central PMCID: PMCPmc192859.
8. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ, et al. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group. N Engl J Med. 2011; 364(20):1897-908. doi: 10.1056/NEJMoa1102673 WOS:000290720700005. PMID: 21526923
9. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012; 119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053 PMID: 22555112; PubMed Central PMCID: PMCNIHMS373947 PMC3389193.
10. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012; 119(7):1399-411. doi: 10.1016/j.ophtha.2012.04.015 PMID: 22578446.
11. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013. Epub 2013/07/23. doi: 10.1016/s0140-6736(13)61501-9 PMID: 23870813.
12. Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013; 120(5):1046-56. doi: 10.1016/j.ophtha.2012.10.014 PMID: 23352196.
13. Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, et al. Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration. Ophthalmology. 2014; 121(11):2181-92. doi: 10.1016/j.ophtha.2014.05.009 PMID: 25015215.
14. Moja L, Lucenteforte E, Kwag Koren H, Bertele V, Campomori A, Chakravarthy U, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews. 2014;(9: ):CD011230. doi: 10.1002/14651858.CD011230.pub2 CD011230.
15. Silva R, Axer Siegel R, Eldem B, Guymer R, Kirchhof B, Papp A, et al. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology. 2013; 120(1):130-9. doi: 10.1016/j.ophtha.2012.07.026 PMID: 23021093
16. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUS-TAIN study. Ophthalmology. 2011; 118(4):663-71. doi: 10.1016/j.ophtha.2010.12.019 PMID: 21459217.
17. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard. PLoS ONE. 2012; 7(8):e42701. doi: 10.1371/journal.pone.0042701 PMID: 22880086
18. Solomon Sharon D, Lindsley K, Vedula Satyanarayana S, Krzystolik Magdalena G, Hawkins Barbara S. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews [Internet]. 2014; (8: ). Available from: http://onlinelibrary.wiley.com/ doi/10.1002/14651858.CD005139.pub3/abstract.
19. Berkman ND, Santaguida PL, Viswanathan M, Morton SC. AHRQ Methods for Effective Health Care. The Empirical Evidence of Bias in Trials Measuring Treatment Differences. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014.
20. Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera AP, Pisella PJ, Gueyffier F, et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol. 2014; 132(11):1317-26. Epub 2014/07/25. doi: 10.1001/jamaophthalmol.2014.2333 PMID: 25058694.
21. Sigford DK, Reddy S, Mollineaux C, Schaal S. Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis. Clin Ophthalmol. 2015; 9:773-81. Epub 2015/ 05/23. doi: 10.2147/opth.s77067 PMID: 25999685; PubMed Central PMCID: PMCPMC4427080.
22. Jiang S, Park C, Barner JC. Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab. J Clin Pharm Ther. 2014; 39(3):234-9. Epub 2014/03/19. doi: 10.1111/jcpt.12146 PMID: 24635444.